Deciphera Pharmaceuticals, Inc. (DCPH)

Market Cap	1.19B
Revenue (ttm)	163.36M
Net Income (ttm)	-194.94M
Shares Out	80.80M
EPS (ttm)	-2.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	414,272
Open	14.57
Previous Close	14.58
Day's Range	14.56 - 15.20
52-Week Range	9.90 - 17.73
Beta	0.39
Analysts	Strong Buy
Price Target	23.00 (+56.78%)
Earnings Date	May 1, 2024

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 28, 2017
• Employees: 355
• Stock Exchange: NASDAQ
• Ticker Symbol: DCPH

Financial Performance

In 2023, DCPH's revenue was $163.36 million, an increase of 21.87% compared to the previous year's $134.04 million. Losses were -$194.94 million, 8.95% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for DCPH stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 56.78% from the latest price.

Price Target

$23.0

(56.78% upside)

Analyst Consensus: Strong Buy